Multi-center Study Demonstrates Significant Reductions in Postoperative Pain and Opioid Use Following Peripheral Nerve Stimulation Treatment
– Findings Published as Congress Demands Review of Medicare Coverage for Non-opioid Treatments –
Cleveland, Ohio- April 26, 2021- Results of a multicenter trial recently published in Anesthesiology, the official peer-reviewed journal of the American Society of Anesthesiologists, demonstrated significant reductions in postoperative opioid use and pain following percutaneous peripheral nerve stimulation (PNS) compared to placebo. Participants undergoing painful orthopedic surgical procedures such as rotator cuff repair were randomized to receive PNS or placebo stimulation as part of the study. Based on the results of the study, lead investigator, Dr. Brian Ilfeld, and co-authors concluded that “percutaneous peripheral nerve stimulation is highly effective for acute pain.”
• Patients treated with PNS consumed 80 percent less opioids in the first seven postoperative days compared to those in the placebo control group (P<0.001).
• Even when taking fewer opioids, patients receiving PNS treatment reported significantly lower pain scores that were one-third of those in the control group (P<0.001).
• None (0 percent) of the patients treated with PNS were using opioids at one month following surgery, while 18 percent of the placebo patients continued taking opioids.
David Dickerson, MD, Chairman, Committee on Pain Medicine, American Society of Anesthesiologists, and section chief for pain medicine, NorthShore University Health System said, “It is clear that surgery and postoperative opioid prescriptions can be a gateway to persistent opioid use and potential opioid use disorder. Furthermore, surpluses of post-surgical opioid prescriptions can be a source of misuse or abuse by individuals for whom the medicines were not prescribed. This study highlights a meaningful role for PNS in the non-opioid management of acute surgical pain. As reflected in the study’s findings, PNS provides a high impact, opioid-sparing, postoperative pain treatment and comes at an important time as Congress is working to identify Medicare payment and coverage policies that promote or unnecessarilyleverage opioids over safe and effective non-opioid treatments. Perioperative PNS treatment provides exactly the kind of evidence-based, FDA-cleared technology for which the NOPAIN Act was drafted. Support for coverage of PNS for acute pain as part of the Congressional initiatives presently underway would be an important step forward in promoting access to a safe and effective non-opioid pain management treatment.”
About the SPRINT® PNS System
The SPRINT® PNS System, by SPR® Therapeutics, marks an innovative shift in the treatment of pain. Our breakthrough, restorative, 60-day treatment is a First-Line™ PNS option uniquely designed to recondition the central nervous system to provide significant and sustained relief from chronic pain — without a permanent implant, nerve destruction or the risk of addiction. The system has been studied extensively for low back pain, shoulder pain, post-amputation pain, and chronic and acute post-operative pain, and is cleared for use up to 60 days. Recognized by leading pain management centers, the breakthrough neuromodulation treatment offers a patient-preferred alternative to more invasive options.
For additional information regarding safety and efficacy visit www.SprintPNS.com.
About SPR Therapeutics, Inc.
SPR Therapeutics is a privately-held medical device company, providing patients with a non-opioid, minimally invasive pain treatment option. Our SPRINT® PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain. Backed by the largest body of clinical evidence, SPR has demonstrated commercial demand in untapped peripheral (shoulder and knee) and back pain markets and built an incredibly strong foundation for commercial growth. Headquartered in Cleveland, OH with satellite offices in Chapel Hill, NC and Minneapolis, MN, SPR’s Senior Management team includes experienced industry veterans with nearly 200 years of collective pain market and MedTech expertise, all driven by our purpose – to improve the quality of patients’ lives by providing them with a minimally invasive, drug-free, surgery-free solution to manage their acute and chronic pain.
More information can be found at www.SPRTherapeutics.com.
SPR Contact:
Mark Stultz
Senior Vice President
